STERLING, Va., August 22, 2019-- Aperiomics, the fast-growing biotech company combining the latest advancements in science, technology, and medicine to change the way healthcare providers identify causes of infection, announced today that they have closed a successful Series A funding round totaling $1.8 million. South Carolina-based investment group VentureSouth leads a group of investors that also includes Pipeline Angels, Propel(x) and a number of high net worth individuals.